August 20, 2020 -- Avid Bioservices and Oragenics have signed an agreement to accelerate the development of a vaccine against COVID-19.
Under the terms of the agreement, Avid will support Oragenics in the development of Terra CoV-2, Oragenics' vaccine candidate that targets the spike protein of SARS-CoV-2. Avid will provide Oragenics with analytical method development, process development, and drug substance manufacturing services.
The companies will first conduct an initial project phase that includes analytical method feasibility and quantification activities. They then plan to advance upstream and downstream process development and manufacture Terra CoV-2 at Avid's Myford facility in Tustin, CA.
Oragenics anticipates the partnership will help the company meet its goal of conducting human clinical trials of the Terra CoV-2 vaccine candidate by early 2021.
Copyright © 2020 scienceboard.net